A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma
Conclusions:
FP/FORM improved lung function and measures of asthma control with comparable efficacy to FP/SAL, and demonstrated a favourable safety and tolerability profile in children aged 4–12 years.
Source: Therapeutic Advances in Respiratory Disease - Category: Respiratory Medicine Authors: Emeryk, A., Klink, R., McIver, T., Dalvi, P. Tags: Original Research Source Type: research
More News: Advair | Advair Diskus | Asthma | Children | Flonase | Flovent | Respiratory Medicine | Study